Interim results reflect Shield’s ongoing delivery in terms of group revenue growth, increased ACCRUFeR® prescription sales and expansion of the average net selling price (NSP) as already outlined in the company’s 1Q25 and 2Q25 trading updates. We maintain our forecasts and reiterate our investment thesis, while management continues to establish a track record of operational focus, with a robust capacity to successfully navigate challenges and build a business driving commercial traction and futu ....
